{
    "cancer_info": {
        "cancer_name": "Castleman Disease"
    },
    "diagnosis_recommendations": {
        "examinations": [
            "Excisional/incisional lymph node biopsy",
            "Core Needle Biopsy (if surgical biopsy inaccessible)",
            "IHC Panel (CD20, CD3, HHV8 LANA, kappa/lambda light chains)",
            "Hematopathology review of all slides",
            "Rebiopsy (if initial biopsy non-diagnostic)",
            "Flow cytometry (blood/biopsy)",
            "EBER-ISH",
            "Molecular analysis (Ig gene rearrangements)",
            "Rule out infections (EBV, CMV, HIV)",
            "Rule out autoimmune disorders (SLE, rheumatoid arthritis)",
            "Rule out malignancies (lymphoma, myeloma)",
            "Hepatitis C testing"
        ]
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "Unicentric CD (UCD)",
            "risk_group": "Surgically resectable",
            "treatment_plans": [
                {
                    "treatment_line": "First-line therapy",
                    "patient_subgroup": "UCD",
                    "plan_name": "Complete resection",
                    "plan_details": "Complete surgical resection (curative)",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Curative regimen"
                }
            ]
        },
        {
            "staging_criteria": "Unicentric CD (UCD)",
            "risk_group": "Unresectable",
            "treatment_plans": [
                {
                    "treatment_line": "First-line therapy",
                    "patient_subgroup": "UCD",
                    "plan_name": "Involved-site RT",
                    "plan_details": "Involved-site radiation therapy (ISRT)",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Recommended regimen"
                },
                {
                    "treatment_line": "First-line therapy",
                    "patient_subgroup": "UCD",
                    "plan_name": "Rituximab ± steroids/cyclophosphamide",
                    "plan_details": "Rituximab with or without steroids/cyclophosphamide",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Recommended regimen"
                },
                {
                    "treatment_line": "First-line therapy",
                    "patient_subgroup": "UCD",
                    "plan_name": "Embolization",
                    "plan_details": "Embolization procedure",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Recommended regimen"
                }
            ]
        },
        {
            "staging_criteria": "Multicentric CD (MCD) - Active Disease",
            "risk_group": "Non-Severe, No Organ Failure",
            "treatment_plans": [
                {
                    "treatment_line": "First-line therapy",
                    "patient_subgroup": "HHV8-negative iMCD",
                    "plan_name": "Siltuximab",
                    "plan_details": "Siltuximab monotherapy",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "First-line therapy",
                    "patient_subgroup": "HHV8-negative iMCD",
                    "plan_name": "Rituximab ± prednisone",
                    "plan_details": "Rituximab with or without prednisone",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Recommended regimen"
                },
                {
                    "treatment_line": "First-line therapy",
                    "patient_subgroup": "HHV8-negative iMCD",
                    "plan_name": "RCVP",
                    "plan_details": "Rituximab, cyclophosphamide, vincristine, prednisone",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Recommended regimen"
                },
                {
                    "treatment_line": "First-line therapy",
                    "patient_subgroup": "HHV8-positive MCD",
                    "plan_name": "Rituximab ± liposomal doxorubicin/prednisone",
                    "plan_details": "Rituximab with or without liposomal doxorubicin and prednisone",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Recommended regimen"
                }
            ]
        },
        {
            "staging_criteria": "Multicentric CD (MCD) - Active Disease",
            "risk_group": "Fulminant/Severe",
            "treatment_plans": [
                {
                    "treatment_line": "First-line therapy",
                    "patient_subgroup": "HHV8-negative iMCD",
                    "plan_name": "R-CHOP",
                    "plan_details": "Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Recommended regimen"
                },
                {
                    "treatment_line": "First-line therapy",
                    "patient_subgroup": "HHV8-negative iMCD",
                    "plan_name": "R-CVAD",
                    "plan_details": "Rituximab, cyclophosphamide, vincristine, doxorubicin, dexamethasone",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Recommended regimen"
                },
                {
                    "treatment_line": "First-line therapy",
                    "patient_subgroup": "HHV8-negative iMCD",
                    "plan_name": "R-CVP",
                    "plan_details": "Rituximab, cyclophosphamide, vincristine, prednisone",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Recommended regimen"
                },
                {
                    "treatment_line": "First-line therapy",
                    "patient_subgroup": "HHV8-negative iMCD",
                    "plan_name": "Siltuximab",
                    "plan_details": "Siltuximab monotherapy",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Recommended regimen"
                },
                {
                    "treatment_line": "First-line therapy",
                    "patient_subgroup": "HHV8-positive MCD",
                    "plan_name": "Rituximab + liposomal doxorubicin",
                    "plan_details": "Rituximab combined with liposomal doxorubicin",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Recommended regimen"
                },
                {
                    "treatment_line": "First-line therapy",
                    "patient_subgroup": "HHV8-positive MCD",
                    "plan_name": "R-CHOP",
                    "plan_details": "Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Recommended regimen"
                },
                {
                    "treatment_line": "First-line therapy",
                    "patient_subgroup": "HHV8-positive MCD",
                    "plan_name": "R-CVP",
                    "plan_details": "Rituximab, cyclophosphamide, vincristine, prednisone",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Recommended regimen"
                }
            ]
        },
        {
            "staging_criteria": "Relapsed/Refractory Disease",
            "risk_group": "HHV8-negative iMCD",
            "treatment_plans": [
                {
                    "treatment_line": "Relapsed/Refractory therapy",
                    "patient_subgroup": "HHV8-negative iMCD",
                    "plan_name": "Siltuximab",
                    "plan_details": "Siltuximab monotherapy",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "Relapsed/Refractory therapy",
                    "patient_subgroup": "HHV8-negative iMCD",
                    "plan_name": "Sirolimus",
                    "plan_details": "Sirolimus monotherapy",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Recommended regimen"
                },
                {
                    "treatment_line": "Relapsed/Refractory therapy",
                    "patient_subgroup": "HHV8-negative iMCD",
                    "plan_name": "Bortezomib + rituximab",
                    "plan_details": "Bortezomib combined with rituximab",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Recommended regimen"
                }
            ]
        },
        {
            "staging_criteria": "Relapsed/Refractory Disease",
            "risk_group": "HHV8-positive MCD",
            "treatment_plans": [
                {
                    "treatment_line": "Relapsed/Refractory therapy",
                    "patient_subgroup": "HHV8-positive MCD",
                    "plan_name": "Liposomal doxorubicin ± rituximab",
                    "plan_details": "Liposomal doxorubicin with or without rituximab",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Recommended regimen"
                },
                {
                    "treatment_line": "Relapsed/Refractory therapy",
                    "patient_subgroup": "HHV8-positive MCD",
                    "plan_name": "High-dose zidovudine/valganciclovir",
                    "plan_details": "High-dose zidovudine combined with valganciclovir",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Recommended regimen"
                }
            ]
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": "HHV8: Dictates antiviral therapy and rituximab use; associated with Kaposi sarcoma flare risk. IL-6 Pathway: Siltuximab (anti-IL-6) is first-line for iMCD; tocilizumab alternative if unavailable. CRP/ESR: Essential for diagnosing active disease and monitoring treatment response. TAFRO-Specific Markers: Thrombocytopenia, reticulin fibrosis, normal immunoglobulins predict aggressive disease course."
    },
    "guideline_id": "（2025.V1）NCCN临床实践指南：Castleman病.txt"
}